
JDRF Celebrates Historic Artificial Pancreas Success Bringing Life-changing Benefits to People with Type 1 Diabetes
If your question was not addressed in the recording, please send it to [email protected]
FDA Approves Medtronic Hybrid Closed Loop System
On September 28, 2016, the type 1 diabetes (T1D) community reached a major breakthrough with the FDA's approval of the Medtronic hybrid closed loop system. The system is the first ever approved to automate the dosing of insulin to reduce high blood sugar levels.
The new Medtronic MiniMed 670G artificial pancreas system is a life-changing breakthrough that allows people with T1D to stay closer to their target blood sugar levels more consistently. JDRF celebrates a decade of dedicated partnership, collaboration, funding and advocacy that have made it possible to reach this landmark goal.
"Today's announcement is a historical achievement for JDRF and the entire T1D community. After years of laying the ground work, this life-changing breakthrough is a true testament to the reason JDRF exists, which is to accelerate ways to cure, prevent and treat this disease," said Derek Rapp, JDRF President and CEO.
The artificial pancreas system is designed to use Medtronic's MiniMed 670G insulin pump, 4th-generation sensors and a control algorithm to automate basal insulin delivery to maximize the time glucose levels are in a healthy range throughout the day and night. The system is fully integrated between the pump and sensor, with no need for a separate smartphone or CGM monitor. The AP system will give many people with T1D new freedom and peace of mind as for the first time, they may be able to sleep through the night without periodically waking up to che
Continue
reading